Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARCT-021 in healthy adults for COVID-19
NCT04668339Phase 2Terminated
- Sponsor
- Arcturus Therapeutics
- Start
- Jan 2021
- Primary completion
- Mar 2022
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 2
01
Overview
A Phase 2 trial of ARCT-021 in coronavirus disease 2019 (COVID-19), sponsored by Arcturus Therapeutics. Started Jan 2021; status: terminated.
02
Drugs
ARCT-021
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04668339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04668339.